A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Stopped Primary objective has been met; safety and pharmacokinetics have been characterized.

Conditions

• Metastases, Neoplasm
• Carcinoma, Non-small Cell Lung
• Renal Cell Carcinoma
• Neuroendocrine Tumors

Interventions

• DRUG: LY2584702
• DRUG: Erlotinib
• DRUG: Everolimus

Sponsor

Eli Lilly and Company